Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

https://doi.org/10.1016/0090-6980(89)90088-9Get rights and content

Abstract

Nicotinic acid (niacin) is a B which is also a potent hypolipidemic agent. However, intense flusing occurs following ingestion of harmacology doses of niacin which greatly limits its usefulness in treating hyperlipidemias. Previous studies have demonstrated that niacin-induced flusing can be substantially attenuated by pre-treatment with cyclooxygenase inhibitors, suggesting that the vasodilation is mediated by a prostaglandin. However, the prostaglandin that presumably mediates the flush has not bee conclusively determined. In this study we report the finding that ingestion of niacin evokes the release of markedly increased quantities of PGD2 in vivo in humans. PGD2 release was assessed by quantification of PGD2 metabolite, 9α 11β-PGF2, in plasma by gas chromatography mass spectrometry.

Following ingestion of 500 mg of niacin in three normal volunteers, intense flushing occurred and plasma levels of 9α, 11β-PGF2 were found to increase dramatically by 800, 430, and 535-fold. Levels of 9α,11β-PGF2 reached a maximum between 12 and 45 min. after ingesting niacin and subsequently declined to near normal levels by 2–4 hours. Levels of 9α, 11β-PGF2 in plasma correlated with the intensity and duration of flushing that occurred in the 3 volunteers.

Release of PGD2 was not accompanied by a release of histamine which was assessed by quantification of plasma levels of the histamine metabolit, Nτ-methylhistamine. The suggests that the origin of the PGD2 release is not the mast cell. Only a modest increase (approximately 2-fold) in the urinary excretion of the prostacyclin metabolite, 2,3-dinor-6-keto-PGF, occurred following ingestion of niacin and no increase in the excretion of the major urinary metabolite of PGE2 was found. These results indicate that the major vasodilatory PG released following ingestion of niacin is PGD2. The fact that markedly increased quantities of PGD2 are released suggests that PGD2 is the mediator of niacin-induced vasodilation in humans.

References (18)

There are more references available in the full text version of this article.

Cited by (201)

  • Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022

    2022, Journal of Allergy and Clinical Immunology: In Practice
    Citation Excerpt :

    Addition of aspirin (975 mg 4 times daily) to the antihistamine program resulted in a decreased excretion of this PGD2 metabolite by 80% to 85% and a cessation of flushing and hypotension in patient 2.13 Following the discovery that aspirin inhibits nicotinic acid–induced flushing,40 subsequent reports documented contemporaneous flush-associated increased plasma levels of 9α,11β-PGF2 in these patients.41 The skin was identified as the major site of PGD2 release after topical application of methylnicotinate (10−1 mol) with plasma levels of 9α,11β-PGF2 rising 25- to 33-fold.42

  • The microvascular response in the skin to topical application of methyl nicotinate: Effect of concentration and variation between skin sites

    2019, Microvascular Research
    Citation Excerpt :

    Methyl nicotinate (MN) is a nicotinic acid, which induces a local cutaneous erythema when topically applied to the skin. The physiologically active compound is the methyl ester of nicotinate, commonly known as the B vitamin niacin (Morrow et al., 1989). Its rubefacient effect is related to a transient increase in the microcirculatory perfusion, which is hypothesized to be mediated through the prostaglandin D2 (PGD2) pathway (Morrow et al., 1989).

View all citing articles on Scopus
View full text